A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide
Autor: | Antonio Finelli, Girish S. Kulkarni, Douglas C. Cheung, Christopher J.D. Wallis, Neil Fleshner, Refik Saskin, Christina Diong, Lisa J. Martin, Dixon T.S. Woon, Shabbir M.H. Alibhai |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
Canada medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Urologists Urology Population Abiraterone Acetate 030232 urology & nephrology Antineoplastic Agents Medical Oncology 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Internal medicine Nitriles Phenylthiohydantoin medicine Humans Enzalutamide Neoplasm Metastasis Practice Patterns Physicians' education Disease burden Aged Neoplasm Staging Oncologists education.field_of_study Proportional hazards model business.industry Hazard ratio Abiraterone acetate Steroid 17-alpha-Hydroxylase Retrospective cohort study medicine.disease Hospitalization Prostatic Neoplasms Castration-Resistant Outcome and Process Assessment Health Care chemistry 030220 oncology & carcinogenesis Benzamides business |
Zdroj: | Urology. 153:147-155 |
ISSN: | 0090-4295 |
Popis: | Objectives To compare toxicity and all-cause mortality for mCRPC patients receiving first line oral systemic therapy prescribed by medical oncologists and urologists. Methods Population-based retrospective cohort study of chemotherapy-naive men aged ≥66 years treated for mCRPC with first-line abiraterone or enzalutamide based on administrative health data (Ontario, Canada, 2012-2017). Primary outcomes were hospitalizations/ER visits for any cause or treatment-related toxicity during first-line mCRPC treatment. Secondary outcome was all-cause mortality. We calculated hazard ratios (HRs) comparing outcomes for different medical specialties using multivariable Cox proportional hazards models. Results Among 3405 mCRPC patients, 2407 (70.7%) received abiraterone and 998 (29.3%) received enzalutamide. 1786 (52.5%) patients visited the ER or were hospitalized. Men treated by medical oncologists had an increased risk of hospitalization/ER visits (HR1.16, 95%CI 1.03-1.31; P = .02), toxicity-related visits (HR1.34, 95%CI 1.08-1.69; P = .01), and mortality (HR1.16, 95%CI 1.02-1.33; P = .02) compared to urologists. Limited information was available, beyond PSA adjustment and prior treatment, on patient disease burden. Conclusion We observed fewer hospital visits overall and for treatment-related toxicity for mCRPC patients who were prescribed first line abiraterone or enzalutamide by urologists compared to medical oncologists. These differences may result from higher prostate cancer disease burden in patients managed by medical oncologists, and/or other unmeasured differences in patient management between specialties. |
Databáze: | OpenAIRE |
Externí odkaz: |